Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey
Filename | 263. Longhurst et al, IOS comparing HAE Type II-II,CEI 2017.pdf |
Filesize | 242.67 KB |
Version | o.263 |
Date added | July 30, 2020 |
Downloaded | 0 times |
Category | Original Work |
Tags | acquired angioedema, Hereditary Angioedema, Icatibant |
Authors | Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M. Fain, O., Fabien, V., and Andresen, I. |
Citation | Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M. Fain, O., Fabien, V., and Andresen, I.: Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey. Clin. Exp. Immunol. 2017: 188; 148-153. |
Corresponding authors | Longhurst, H. J. |
DocNum | O.263 |
DocType | |
Edition; Page | 188; 148-153 |
IF | 3.54 |
Publisher | Clin. Exp. Immunol. |
ReleaseDate | 2017 |
Icatibant is used to treat acute hereditary angioedema with C1 inhibitordeficiency types I/II (C1-INH-HAE types I/II) and has shown promise inangioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Datafrom the Icatibant Outcome Survey (IOS) were analysed to evaluate theeffectiveness of icatibant in the treatment of patients with C1-INH-AAE andcompare disease characteristics with those with C1-INH-HAE types I/II. Keymedical history (including prior occurrence of attacks) was recorded uponIOS enrolment. Thereafter, data were recorded retrospectively atapproximately 6-month intervals during patient follow-up visits. In theicatibant-treated population, 16 patients with C1-INH-AAE had 287 attacksand 415 patients with C1-INH-HAE types I/II had 2245 attacks. Patientswith C1-INH-AAEversusC1-INH-HAE types I/II were more often male (69versus42%;P50035) and had a significantly later mean (95% confidenceinterval) age of symptom onset [579 (5133–6453)versus140 (1270–1526) years]. Time from symptom onset to diagnosis was significantlyshorter in patients with C1-INH-AAEversusC1-INH-HAE types I/II (mean123 monthsversus1181 months;P50006). Patients with C1-INH-AAEshowed a trend for higher occurrence of attacks involving the face (35versus21% of attacks;P50064). Overall, angioedema attacks were more severe inpatients with C1-INH-HAE types I/IIversusC1-INH-AAE (61versus40% ofattacks were classified as severe to very severe;P<0001). Median totalattack duration was 50hand90 h for patients with C1-INH-AAEversusC1-INH-HAE types I/II, respectively.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.